Koers Iovance Biotherapeutics Inc Nasdaq
Aandelen
US53619R1023
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 153 mln. 141 mln. | Omzet 2025 * | 428 mln. 395 mln. | Marktkapitalisatie | 2,71 mld. 2,5 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -356 mln. -328 mln. | Nettowinst (verlies) 2025 * | -199 mln. -183 mln. | EV/omzet 2024 * | 17,3 x |
Nettoliquiditeiten 2024 * | 72,44 mln. 66,8 mln. | Nettoliquiditeiten 2025 * | 144 mln. 133 mln. | EV/omzet 2025 * | 6 x |
K/w-verhouding 2024 * |
-7,43
x | K/w-verhouding 2025 * |
-14,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,57% |
Recentste transcriptie over Iovance Biotherapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30-09-16 |
Director of Finance/CFO | 51 | 14-12-20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20-07-11 |
Director/Board Member | 56 | 07-06-16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-36,44% | 8,68 mld. | |
-3,29% | 3,2 mld. | |
-18,71% | 2,04 mld. | |
-22,03% | 1,64 mld. | |
+64,58% | 1,43 mld. | |
+34,58% | 841 mln. | |
-7,42% | 718 mln. | |
-25,51% | 538 mln. | |
-3,38% | 287 mln. |